Recombinant human erythropoietin with advantageous glycosylation profile
CA 2303476 A1 · Owner: Hermentin, Peter · Inventors: Fibi, Mathias; Hermentin, Peter
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Described are polypeptides having part or all of the primary structural conformation and biological property of erythropoietin and having an improved in vivo half-life and biological activity due to a modified glycosylation profile. Also provided are DNA sequences encoding the amino acid sequence of said polypeptide operatively linked to regulatory elements which allow for the expression of said DNA sequence in the eukaryotic host cell as well as vectors comprising such DNA sequences. Furthermore host cells comprising the , aforementioned DNA sequences and vectors and their use for the production of the aforedescribed polypeptide are described. Pharmaceutical and diagnostic …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 26, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 26, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 26, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.